Get started
Author

Wenwen Chai

Observed institution: Hunan Cancer Hospital
ORCID: 0009-0001-5787-138X
Observed ORCID: 0009-0001-5787-138X
OpenAlex ID: A5133301784
Data from AL2846, a Novel Multi-Kinase Inhibitor, for Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer: Exploratory Clinical Results From the Phase Ib Study
2026 · Feng Shi, Wenwen Chai, et al.
Supplementary figure 1 from AL2846, a Novel Multi-Kinase Inhibitor, for Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer: Exploratory Clinical Results From the Phase Ib Study
2026 · Feng Shi, Wenwen Chai, et al.
Supplementary figure 2 from AL2846, a Novel Multi-Kinase Inhibitor, for Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer: Exploratory Clinical Results From the Phase Ib Study
2026 · Feng Shi, Wenwen Chai, et al.
Supplementary Data1 from AL2846, a Novel Multi-Kinase Inhibitor, for Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer: Exploratory Clinical Results From the Phase Ib Study
2026 · Feng Shi, Wenwen Chai, et al.
AL2846, a Novel Multi-Kinase Inhibitor, for Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer: Exploratory Clinical Results From the Phase Ib Study
2026 · Feng Shi, Wenwen Chai, et al. · Clinical Cancer Research
Works count: 5
Citation count:
H-index:
I10-index:
Year
Topic
Type